Estrone (E1) Rate-of-Change Interpretation: What Your Labs Actually Mean

What Estrone (E1) Is and Why It Matters

Estrone is one of three naturally occurring estrogens, sitting alongside estradiol (E2) and estriol (E3) in the hormonal hierarchy. In reproductive-age women, E2 dominates; after the final menstrual period, E1 takes over as the primary circulating estrogen. The shift matters clinically because E1 binds estrogen receptors with roughly one-third the affinity of E2, meaning tissue effects per picomole are weaker, but circulating concentrations can remain substantial for decades. The Endocrine Society's clinical practice guideline on menopause notes that postmenopausal estrogen concentrations depend heavily on body composition and aromatase activity in peripheral tissues.

Understanding E1 in isolation is useful. Understanding how it is moving over time is far more useful.

The Biochemical Origin of Postmenopausal Estrone

After ovarian follicular activity ceases, the adrenal cortex continues secreting androstenedione. Aromatase enzymes in adipose stromal cells convert androstenedione to estrone at a rate that scales with fat mass. A landmark study in the Journal of Clinical Endocrinology and Metabolism demonstrated that aromatase activity in adipose tissue accounts for the majority of circulating estrogen in postmenopausal women, which is why BMI is one of the strongest predictors of postmenopausal E1 levels.

Estrone can also be converted reversibly to estradiol by 17beta-hydroxysteroid dehydrogenase. This interconversion means elevated E1 can silently raise E2 in target tissues even when serum E2 appears normal.

E1 Versus E2: Why Both Must Be Measured

Measuring only E2 during postmenopausal hormone therapy misses the full estrogenic picture. Oral estradiol preparations, in particular, undergo significant first-pass hepatic metabolism that converts a substantial fraction of the dose to estrone. Research published in Menopause showed that oral 17beta-estradiol produces E1:E2 ratios of approximately 5:1, whereas transdermal estradiol maintains a more physiological ratio near 1:1. Tracking both analytes together is therefore standard practice when evaluating a patient's full estrogenic load.

Estrone Normal Range and Reference Intervals

Reference ranges for E1 depend on menopausal status, the assay platform used, and the laboratory. These numbers are not interchangeable across labs.

Postmenopausal Reference Ranges

Most clinical laboratories report postmenopausal E1 between 10 and 50 pg/mL when measured by immunoassay. LC-MS/MS methods, which offer superior specificity at low concentrations, often yield slightly lower values for the same sample. The CDC's hormone standardization program (HoSt) has documented significant inter-laboratory variability in estrogen measurement at postmenopausal concentrations, which is why a patient's serial measurements should always be compared within the same laboratory and assay platform.

Values above 50 pg/mL in the absence of exogenous estrogen may warrant investigation. Causes include elevated BMI, adrenal androgen excess, aromatase-producing tumors (rare), or undisclosed use of phytoestrogen supplements.

Premenopausal Reference Ranges

During the menstrual cycle, E1 fluctuates in phase with E2:

• Follicular phase: approximately 30 to 170 pg/mL
• Midcycle surge: can peak above 200 pg/mL
• Luteal phase: approximately 60 to 140 pg/mL

Premenopausal E1 tracking is less commonly the primary clinical focus, but rate-of-change data are relevant when evaluating ovarian reserve, anovulation, or the perimenopause transition, where E1:E2 ratios shift before cycle irregularity becomes obvious.

What "Optimal" Means in a Clinical Context

The word "optimal" has no single regulatory definition for E1. No major guideline assigns a target E1 number the way lipid guidelines assign an LDL target. What clinicians actually track is symptom resolution, bone-density trajectory, and cardiovascular surrogate markers, with E1 as one supporting data point among several. The North American Menopause Society's 2023 position statement on hormone therapy emphasizes individualized assessment rather than a fixed serum estrogen target.

A reasonable functional target in postmenopausal women receiving HRT is an E1 level that correlates with symptom relief (typically when E2 is in the 40 to 100 pg/mL range on therapy), without producing signs of estrogen excess such as breast tenderness, uterine bleeding, or abnormal endometrial thickness on ultrasound.

How to Interpret Rate-of-Change Data

A single estrone result is a photograph. Rate-of-change data is the film.

Why Serial Measurements Outperform Spot Values

Estrone concentrations fluctuate based on meal timing, stress-related cortisol-androgen interactions, recent exercise, and acute changes in fat mass. A single elevated value may represent biological noise. Two values collected 8 to 12 weeks apart under standardized conditions (fasting morning draw, same lab, same assay platform) begin to reveal a real trend. Three values confirm it.

Rate-of-change is calculated simply: subtract the earlier value from the later value, divide by the number of weeks between draws, and express the result in pg/mL per week. A rate of change greater than +2 pg/mL per week sustained over 8 weeks signals a meaningful upward trajectory that warrants clinical review.

Interpreting a Rising E1

A rising E1 trajectory in a postmenopausal woman not on therapy most commonly reflects:

1. Weight gain increasing adipose aromatization
2. Adrenal androgen excess (check DHEA-S and androstenedione)
3. New or increased use of phytoestrogen-rich foods or supplements

A rising E1 in a woman already on oral estradiol may simply reflect dose accumulation during the first 6 to 8 weeks of a new regimen. Pharmacokinetic data published in the Journal of Clinical Pharmacology show that steady-state estrone concentrations on oral estradiol 1 mg/day are typically reached by week 4 to 6. If E1 continues to rise beyond week 8 on a stable oral dose, dose reduction or a switch to transdermal delivery is worth considering.

Interpreting a Falling E1

A declining E1 on no therapy usually tracks with weight loss or reduced adrenal androgen output. On therapy, a falling E1 alongside persistent vasomotor symptoms suggests inadequate estrogenic effect and may indicate poor oral absorption, rapid hepatic first-pass clearance, or non-adherence.

A falling E1 in a woman with osteopenia or osteoporosis is a signal to reassess bone-protective coverage. The Women's Health Initiative observational data (N=93,676) showed that postmenopausal women with lower estrone concentrations had significantly higher rates of hip fracture compared to those with E1 above 10 pg/mL.

The E1:E2 Ratio as a Rate-of-Change Adjunct

Tracking the E1:E2 ratio alongside absolute values adds interpretive power. On transdermal estradiol, the ratio should stay near 1:1. On oral estradiol, a ratio above 5:1 suggests heavy first-pass conversion and may explain suboptimal symptom control despite adequate-seeming E2 levels, because E1's weaker receptor binding translates to less tissue effect per unit concentration. Monitoring both analytes at each interval draw takes less than one additional tube of blood and meaningfully refines clinical decision-making.

Assay Selection and Preanalytic Variables

LC-MS/MS Versus Immunoassay

Immunoassay platforms dominate most commercial labs due to throughput and cost, but they have known cross-reactivity issues at low estrogen concentrations. A comparative study in Clinical Chemistry found that immunoassay-measured estradiol in postmenopausal women overestimated true concentrations by 20 to 40% compared to LC-MS/MS reference methods. The same principle applies to E1. When absolute accuracy matters, particularly for patients with very low baseline values or when fine-tuning low-dose HRT, LC-MS/MS is the preferred method.

Request the assay type from the ordering lab before comparing two results obtained on different platforms. Treating an LC-MS/MS value of 18 pg/mL and an immunoassay value of 18 pg/mL as equivalent will introduce systematic error into your rate-of-change calculation.

Timing and Preanalytic Standardization

For serial rate-of-change tracking, standardize the draw conditions at every visit:

• Fasting for at least 8 hours before the draw
• Morning draw (between 7:00 and 9:00 AM) to reduce diurnal adrenal androgen variation
• No vigorous exercise in the 24 hours before the draw
• For women on oral estradiol, draw at trough (12 to 14 hours post-dose)
• For women on transdermal patches, draw at midcycle of the patch wear interval

Non-standardized draws introduce noise that can mimic a rate-of-change signal. The Endocrine Society's laboratory guidelines recommend standardizing preanalytic conditions for all serial hormone measurements to minimize within-person coefficient of variation.

Clinical Decision Framework for E1 Rate-of-Change

The following decision framework is used by the HealthRX medical team when reviewing serial estrone data. It integrates absolute value, rate-of-change velocity, the E1:E2 ratio, and clinical context.

Step 1: Establish the Baseline

Obtain two fasting morning E1 and E2 values on the same assay platform, 4 to 8 weeks apart before initiating or adjusting therapy. This establishes the patient's endogenous production rate, which is the floor against which all future changes are measured.

Step 2: Apply the 8-Week Rule

Recheck E1 and E2 at 8 weeks after any dose change. Steady state on oral estradiol is achieved by week 4 to 6; on weekly transdermal patches, by week 2 to 3. An 8-week check therefore captures true steady-state pharmacokinetics rather than transitional flux.

Step 3: Calculate Rate-of-Change Velocity

Use the formula: (E1 week-8 minus E1 week-0) divided by 8 = pg/mL per week.

• Rate < +1 pg/mL per week with symptom relief: continue current regimen, recheck in 12 weeks
• Rate between +1 and +2 pg/mL per week: acceptable on oral estradiol, watch for signs of estrogen excess at 12-week recheck
• Rate > +2 pg/mL per week: review dose, delivery route, and concomitant aromatase substrate load (adipose mass, adrenal androgens)
• Negative rate with persistent symptoms: assess adherence, absorption, and consider dose uptitration

Step 4: Integrate E1:E2 Ratio

If E1:E2 exceeds 5:1 on oral therapy with inadequate symptom control, switching to transdermal estradiol 0.05 to 0.1 mg/day may restore a more physiological ratio and improve tissue-level estrogenic effect without increasing total estrogenic load.

Step 5: Reassess at 12-Week Intervals

Once stable (two consecutive draws showing rate-of-change <1 pg/mL per week), shift to quarterly monitoring. Annual monitoring is appropriate when the patient has been on a stable regimen for more than 12 months and is asymptomatic.

Estrone in Special Clinical Scenarios

Obesity and Aromatase Excess

Adipose aromatization is the primary driver of elevated endogenous E1 in postmenopausal women. A BMI increase from 25 to 35 kg/m² may roughly double circulating E1. Epidemiological data from the EPIC study (N=755 postmenopausal women) showed that each 5-unit increase in BMI was associated with an approximately 35% higher serum estrone concentration. In obese patients, E1 may already be in the range of 60 to 100 pg/mL without any exogenous hormone use, which affects both the risk-benefit calculation for HRT and the monitoring thresholds used.

Breast Cancer Risk Consideration

Long-term exposure to elevated E1 is associated with increased breast tissue stimulation. A nested case-control analysis within the Nurses' Health Study showed that postmenopausal women in the highest quartile of serum estrone had a relative risk of breast cancer of approximately 2.0 compared to women in the lowest quartile. This does not mean E1 should be suppressed to the lowest detectable level in all women; the tradeoff against bone density, cardiovascular protection, and quality of life must be individualized. But it does justify including E1 in the monitoring panel rather than relying on E2 alone.

GLP-1 Receptor Agonist Use and E1

Women using semaglutide or tirzepatide for weight management may experience a measurable decline in E1 as adipose mass decreases. This effect is generally favorable from a breast cancer risk standpoint, but it may unmask vasomotor symptoms in women who were previously compensating with aromatase-derived estrogen. Track E1 before and during significant weight loss (greater than 10% of body weight) to anticipate the need for HRT initiation or dose adjustment.

Progesterone Co-Administration and E1 Monitoring

Any woman with an intact uterus receiving exogenous estrogen, or any woman with elevated endogenous E1 sufficient to produce endometrial stimulation, requires adequate progestogen coverage. The guideline rationale is direct: the PEPI trial (N=875) demonstrated that unopposed estrogen produced endometrial hyperplasia in 62% of women over 3 years versus 2% in women receiving combined estrogen-progestogen therapy.

Elevated E1 on rate-of-change trending upward, without concurrent progestogen use in a woman with a uterus, is an actionable finding. Document it and address it at the same visit.

Patient Communication: Translating Rate-of-Change Data

Telling a patient her E1 is 38 pg/mL means little without context. A more useful communication approach:

"Your estrone level was 22 pg/mL three months ago and is 38 pg/mL today. That's a rise of about 2 pg/mL per week. Given that you're on a stable oral estradiol dose, this rise is likely explained by the weight gain you mentioned. We should recheck in 8 weeks and consider whether a lower dose or a patch would better match your body's current hormone production."

This framing gives the patient a trajectory, a probable cause, and a clear next step. It anchors the lab value in a clinical story rather than leaving it as an abstract number.